aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Nexo Therapeutics, founded with a mission to innovate in the field of oncology, focuses on the discovery and development of small molecule drugs for cancer patients who currently lack effective treatment options. Their core vision is to address some of cancer's most elusive targets by leveraging the intersection of biology and chemistry. Nexo Therapeutics offers a specialized approach to drug discovery, targeting diseases where traditional methods have failed due to the absence of quality ligands and limited pharmacological understanding.
Notable figures affiliated with Nexo Therapeutics include leading scientists and industry experts in oncology and drug development. The company has attracted significant investment from top-tier venture capital firms specializing in biotech innovations. Key achievements include advancing several promising drug candidates into preclinical development stages, demonstrating their potential to fill critical gaps in cancer treatment. Overall, Nexo Therapeutics is making a substantial impact by pioneering new therapeutic avenues and offering hope to patients with limited options.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Oncology Drugs
Technology
Biotech
Tags
SaaS
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Nexo Therapeutics founded?
Nexo Therapeutics was founded in 2022.
Where is Nexo Therapeutics's headquarters located?
Nexo Therapeutics's headquarters is located in Littleton, CO, US.
When was Nexo Therapeutics's last funding round?
Nexo Therapeutics's most recent funding round was for $60M (USD) in July 2023.
How many employees does Nexo Therapeutics have?
Nexo Therapeutics has 30 employees as of Feb 5, 2024.
How much has Nexo Therapeutics raised to-date?
As of July 05, 2023, Nexo Therapeutics has raised a total of $60M (USD) since Jul 26, 2023.
Add Comparison
Total Raised to Date
$60M
USD
Last Update Jul 26, 2023
Last Deal Details
$60M
USD
Jul 26, 2023
Series A
Total Employees Over Time
30
As of Feb 2024
Nexo Therapeutics Address
11757 W. Ken Caryl Avenue
Suite F 520
Littleton,
Colorado
80127-3719
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts